title: [Descriptive study of a serie of patients affected by progressive supranuclear palsy].
abstract: BACKGROUND
  Progressive supranuclear palsy is a neurodegenerative disorder affecting diverse neurologic systems. The actual treatment response is poor in most patients.
  
  
  OBJECTIVE
  review of a long series of patients affected by PSP in several aspects.
  
  
  METHODS
  A series of patients was reviewed by means of the register questionnaire of PSP in Spain (from PSP Disabling Rating Scale and Staging System). This is carried out on the patients when the diagnostic is done. It was achieved a descriptive of the patients, in several aspects, and an evaluation of the treatment in relation to the dose and the duration.
  
  
  RESULTS
  In general, the age of diagnostic is 66 years, there is not neurological illness in the family, falls and disorders of gait are the most representative parameters. The neuroimage shows fronto temporal atrophy. The treatment response is poor, despite the dose and the duration.
  
  
  CONCLUSIONS
  Our series confirms the typical dates of the illness an the poor response to treatment with L Dopa.
authors.affiliation: Servicio de Neurología; Hospital Universitario La Fe, Valencia, 46009, España.
authors.forename: V E
authors.initials: VE
authors.lastname: Villanueva-Haba
authors.forename: M
authors.initials: M
authors.lastname: Garcés
authors.forename: A
authors.initials: A
authors.lastname: de Vera
authors.forename: C
authors.initials: C
authors.lastname: Valero
authors.forename: J A
authors.initials: JA
authors.lastname: Burguera
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015259:Dopamine Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013494:Supranuclear Palsy, Progressive / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D015259:Dopamine Agents; D007980:Levodopa